Relationship between circulating adipokines and cholesterol efflux in subjects with severe carotid atherosclerosis.

[1]  S. Daskalopoulou,et al.  Expression of Resistin, Chemerin, and Chemerin’s Receptor in the Unstable Carotid Atherosclerotic Plaque , 2021, Stroke.

[2]  Yanlin Wang,et al.  Mechanisms of Adiponectin in Regulation of Proinflammatory Cytokine Production and Migration in Macrophages , 2021, Journal of inflammation research.

[3]  S. Daskalopoulou,et al.  Adiponectin's mechanisms in high-density lipoprotein biogenesis and cholesterol efflux. , 2020, Metabolism: clinical and experimental.

[4]  H. Ye,et al.  Cholesterol efflux capacity in coronary artery disease: a meta-analysis , 2020, Coronary artery disease.

[5]  G. Fink,et al.  Chemerin contributes to in vivo adipogenesis in a location-specific manner , 2020, PloS one.

[6]  C. Weber,et al.  Hematopoietic ChemR23 (Chemerin Receptor 23) Fuels Atherosclerosis by Sustaining an M1 Macrophage-Phenotype and Guidance of Plasmacytoid Dendritic Cells to Murine Lesions—Brief Report , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Tall,et al.  Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[8]  S. Daskalopoulou,et al.  Adiponectin and cholesterol efflux. , 2019, Metabolism: clinical and experimental.

[9]  I. Rudež,et al.  Association between Circulatory and Plaque Resistin Levels with Carotid Plaque Instability and Ischemic Stroke Events. , 2018, The heart surgery forum.

[10]  Chang-Hoon Lee,et al.  Globular Adiponectin Exerts a Pro-Inflammatory Effect via IκB/NF-κB Pathway Activation and Anti-Inflammatory Effect by IRAK-1 Downregulation , 2018, Molecules and cells.

[11]  G. Aust,et al.  Increased circulating chemerin in patients with advanced carotid stenosis , 2018, BMC Cardiovascular Disorders.

[12]  M. Sata,et al.  Roles of Perivascular Adipose Tissue in the Pathogenesis of Atherosclerosis , 2018, Front. Physiol..

[13]  G. Pregartner,et al.  Adiponectin Predicts High‐Density Lipoprotein Cholesterol Efflux Capacity in Adults Irrespective of Body Mass Index and Fat Distribution , 2017, The Journal of clinical endocrinology and metabolism.

[14]  C. Mantzoros,et al.  Adiponectin, lipids and atherosclerosis , 2017, Current opinion in lipidology.

[15]  M. J. Kim,et al.  Globular Adiponectin Inhibits Lipopolysaccharide-Primed Inflammasomes Activation in Macrophages via Autophagy Induction: The Critical Role of AMPK Signaling , 2017, International journal of molecular sciences.

[16]  Yingying Guo,et al.  Effect of adiponectin on macrophage reverse cholesterol transport in adiponectin-/- mice and its mechanism , 2017, Experimental and therapeutic medicine.

[17]  S. Daskalopoulou,et al.  Decreased Adiponectin-Mediated Signaling Through the AdipoR2 Pathway Is Associated With Carotid Plaque Instability , 2017, Stroke.

[18]  C. Mantzoros,et al.  Circulating Chemerin Is Associated With Carotid Plaque Instability, Whereas Resistin Is Related to Cerebrovascular Symptomatology , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Y. Zhang,et al.  Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study. , 2016, Atherosclerosis.

[20]  P. Mancuso.  The role of adipokines in chronic inflammation , 2016, ImmunoTargets and therapy.

[21]  J. Genest,et al.  HDL-Mediated Cellular Cholesterol Efflux Assay Method. , 2015, Annals of clinical and laboratory science.

[22]  D. Rader,et al.  Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.

[23]  M. Budoff,et al.  The association of resistin with cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. , 2015, Atherosclerosis.

[24]  Zahra Bazi,et al.  Adiponectin as a potential biomarker of vascular disease , 2015, Vascular health and risk management.

[25]  B. Trimarco,et al.  Adipokines, Vascular Wall, and Cardiovascular Disease , 2015, Angiology.

[26]  Simon L Bacon,et al.  The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2013, The Canadian journal of cardiology.

[27]  R. Bai,et al.  Adiponectin upregulates ABCA1 expression through liver X receptor alpha signaling pathway in RAW 264.7 macrophages. , 2015, International journal of clinical and experimental pathology.

[28]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[29]  S. Daskalopoulou,et al.  Cholesterol Efflux Capacity, Carotid Atherosclerosis, and Cerebrovascular Symptomatology , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[30]  V. Oktay,et al.  Relationship Between Increased Serum Resistin Level and Severity of Coronary Artery Disease , 2014, Angiology.

[31]  M. Xia,et al.  Adiponectin increases macrophages cholesterol efflux and suppresses foam cell formation in patients with type 2 diabetes mellitus. , 2013, Atherosclerosis.

[32]  S. Hazen,et al.  Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[33]  J. Genest,et al.  HDL, Atherosclerosis, and Emerging Therapies , 2013, Cholesterol.

[34]  M. Blüher.  Adipose tissue dysfunction contributes to obesity related metabolic diseases. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[35]  G. Luc,et al.  Multiple Biomarkers for the Prediction of Ischemic Stroke: The PRIME Study , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[36]  M. Landray,et al.  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.

[37]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[38]  L. Xiaotao,et al.  Serum chemerin levels are associated with the presence and extent of coronary artery disease , 2012, Coronary artery disease.

[39]  E. Jorge-Galarza,et al.  Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl. , 2012, The American journal of cardiology.

[40]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[41]  D. Strunk,et al.  Globular domain of adiponectin: promising target molecule for detection of atherosclerotic lesions , 2011, Biologics : targets & therapy.

[42]  A. Zimmer,et al.  Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques , 2011, International journal of nanomedicine.

[43]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[44]  D. Greaves,et al.  Chemerin Contributes to Inflammation by Promoting Macrophage Adhesion to VCAM-1 and Fibronectin through Clustering of VLA-4 and VLA-5 , 2010, The Journal of Immunology.

[45]  M. Phillips,et al.  High density lipoprotein structure-function and role in reverse cholesterol transport. , 2010, Sub-cellular biochemistry.

[46]  C. Mantzoros,et al.  Adiponectin in insulin resistance: lessons from translational research. , 2010, The American journal of clinical nutrition.

[47]  M. Reiser,et al.  Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. , 2009, European journal of endocrinology.

[48]  M. Xu,et al.  The expression of ATP-binding cassette transporter A1 in Chinese overweight and obese patients , 2009, International Journal of Obesity.

[49]  D. Rader,et al.  The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis This work was supported by P01-HL22633 from the NHLBI. Published, JLR Papers in Press, December 8, 2008. , 2009, Journal of Lipid Research.

[50]  G. Watts,et al.  Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. , 2009, The Journal of clinical endocrinology and metabolism.

[51]  Peng Zhang,et al.  Overexpression of Adiponectin Receptors Potentiates the Antiinflammatory Action of Subeffective Dose of Globular Adiponectin in Vascular Endothelial Cells , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[52]  L. Tian,et al.  Adiponectin reduces lipid accumulation in macrophage foam cells. , 2009, Atherosclerosis.

[53]  F. Visseren,et al.  Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. , 2008, European heart journal.

[54]  T. Yoshimura,et al.  Chemerin reveals its chimeric nature , 2008, The Journal of experimental medicine.

[55]  M. Phillips,et al.  Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I. , 2008, Journal of lipid research.

[56]  D. Greaves,et al.  Synthetic chemerin-derived peptides suppress inflammation through ChemR23 , 2008, The Journal of experimental medicine.

[57]  P. Park,et al.  Mechanisms for the anti‐inflammatory effects of adiponectin in macrophages , 2008, Journal of gastroenterology and hepatology.

[58]  A. Xu,et al.  Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. , 2008, Clinical science.

[59]  A. Xu,et al.  Post-translational modifications of adiponectin: mechanisms and functional implications. , 2008, The Biochemical journal.

[60]  H. Nakazawa,et al.  Validation of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol , 2007, Journal of clinical biochemistry and nutrition.

[61]  G. Watts,et al.  Effect of Weight Loss on LDL and HDL Kinetics in the Metabolic Syndrome , 2007, Diabetes Care.

[62]  C. Rae,et al.  Resistin induces lipolysis and re‐esterification of triacylglycerol stores, and increases cholesteryl ester deposition, in human macrophages , 2007, FEBS letters.

[63]  E. Butcher,et al.  Chemerin, a Novel Adipokine That Regulates Adipogenesis and Adipocyte Metabolism* , 2007, Journal of Biological Chemistry.

[64]  S. Kihara,et al.  Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. , 2007, Biochemical and biophysical research communications.

[65]  T. Kadowaki,et al.  Selective purification and characterization of adiponectin multimer species from human plasma. , 2007, Biochemical and biophysical research communications.

[66]  T. Tsao,et al.  The oligomeric structure of high molecular weight adiponectin , 2007, FEBS letters.

[67]  T. Mountokalakis,et al.  Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[68]  Weibin Xu,et al.  Resistin increases lipid accumulation and CD36 expression in human macrophages. , 2006, Biochemical and biophysical research communications.

[69]  P. Gambert,et al.  Adiponectin Is an Important Determinant of ApoA-I Catabolism , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[70]  A. Tedgui,et al.  Cytokines in atherosclerosis: pathogenic and regulatory pathways. , 2006, Physiological reviews.

[71]  Anil Kumar Singh,et al.  Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. , 2005, Biochemical and biophysical research communications.

[72]  J. Schneider,et al.  Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. , 2005, Diabetes care.

[73]  Anand Rohatgi,et al.  Resistin Is an Inflammatory Marker of Atherosclerosis in Humans , 2005, Circulation.

[74]  T. Kadowaki,et al.  Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. , 2005, Endocrinology.

[75]  T. Saruta,et al.  Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. , 2004, The Journal of clinical endocrinology and metabolism.

[76]  S. Kihara,et al.  Obesity, adiponectin and vascular inflammatory disease , 2003, Current opinion in lipidology.

[77]  S. Verma,et al.  Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction , 2003, Circulation.

[78]  T. Saruta,et al.  Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. , 2002, Clinical science.

[79]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[80]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.